I'm thinking prurisol interim data, if good to go, will be an excellent trigger. Double blind reported by the third party completely out of Leo's hands adds so much validity to the entire platform. I have no issue with trust, that's just how these trials come through. If results are good, we start pricing in potential approval/ sale of the drug.

But this is only my opinion.